Report / Paper metadata
A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.
A biomedical paper record. This page preserves its title, publication metadata and identifier, not the full article. The title alone does not establish the study findings or their clinical importance.
Limits
No clinical review has been performed. This record is not a treatment recommendation, eligibility confirmation or current availability guarantee.
- Kind
- Paper metadata